


Drug-Drug Interactions for Therapeutic Biologics
Zhou, H. — Meibohm, B.
ISBN-13: 9781118032169
WILEY
Agosto / 2013
1ª Edición
Inglés
Tapa dura
386 pags
800 gr
x x cm
Recíbelo en un plazo De 7 a 10 días
Description
Strategize, plan, and execute comprehensive drug-drug interaction assessments for therapeutic biologics
Offering both theory and practical guidance, this book fully explores drug-drug interaction assessments for therapeutic biologics during the drug development process. It draws together and analyzes all the latest findings and practices in order to present our current understanding of the topic and point the way to new research. Case studies and examples, coupled with expert advice, enable readers to better understand the complex mechanisms of biologic drug-drug interactions.
Drug-Drug Interactions for Therapeutic Biologics features contributions from leading international experts in all areas of therapeutic biologics drug development and drug-drug interactions. The authors' contributions reflect a thorough review and analysis of the literature as well as their own firsthand laboratory experience. Coverage includes such essential topics as:
• Drug-drug interaction risks in combination with small molecules and
other biologics
• Pharmacokinetic and pharmacodynamic drug-drug interactions
• In vitro methods for drug-drug interaction assessment and prediction
• Risk-based strategies for evaluating biologic drug-drug interactions
• Strategies to minimize drug-drug interaction risk and mitigate toxic
interactions
• Key regulations governing drug-drug interaction assessments for therapeutic
biologics.
Drug-Drug Interactions for Therapeutic Biologics is recommended for pharmaceutical and biotechnology scientists, clinical pharmacologists, medicinal chemists, and toxicologists. By enabling these readers to understand how therapeutic biologics may interact with other drugs, the book will help them develop safer, more effective therapeutic biologics.
Table of Contents
Chapter 1: Drug Interactions for Therapeutic Proteins: A Journey Just Beginning
Honghui Zho and Bernd Meibohm
Chapter 2: Pharmacokinetic and Pharmacodynamic-Based Drug Interactions for
Therapeutic Proteins
Dan Lu, SandhyaGirish Frank-Peter Theil and Amita Joshi
Chapter 3: Drug Interaction Assessment Strategies: Small Molecules versus Therapeutic
Proteins
Shannon Dallas, Carlo Sensenhauser, SouvikChattopadhyay and Jose Silva
Chapter 4: Model-Independent and Modeling-Based Methods to Assess Drug-Drug
Interactions for Therapeutic Proteins
Di Wu and Jeffrey Barrett
Chapter 5: Utility of in vitroMethods in Drug-Drug Interaction Assessment and
Prediction for Therapeutic Biologics
Theresa Nguyen, Narendra Kishnani, and Raymond Evers
Chapter 6: Use of Animal Models for Projection of Clinical Drug-Drug Interactions
for Therapeutic Proteins
Eugenia Kraynov and Martin E. Dowty
Chapter 7: The ‘Cocktail’ Approach and its Utility in Drug-Drug
Interaction Assessments for Therapeutic Proteins
Alexander Jetter and UweFuhr
Chapter 8: Logistic Considerations in Study Design for Biologic Drug-Drug Interaction
Assessments
Min Zhu and Yu-Nien (Tom) Sun
Chapter 9: Statistical Considerations in Assessing Drug-Drug Interactions for
Therapeutic Proteins
Chuanpu Hu and Honghui Zhou
Chapter 10: FDA Perspectives on Therapeutic Protein Drug-Drug Interaction Assessments
Hong Zhao, Lei Zhang, Kellie Reynolds, and Shiew-Mei Huang
Chapter 11: Disease-Drug-Drug Interaction Assessments for Tocilizumab –
a Monoclonal Antibody against Interleukin-6 Receptor to Treat Patients with
Rheumatoid Arthritis
Xiaoping Zhang and Barbara J. Brennan
Chapter 12: Drug-Drug Interactions for Etanercept – a Fusion Protein
Joan Korth-Bradley
Chapter 13: Drug Interactions of Cytokines and Anti-cytokine Therapeutic Proteins
J. GregSlatter, L.C. Wienkers and Leslie J. Dickmann
Chapter 14: Drug Interactions for Growth Factors and Hormones
Yow-Ming Wang and TarundeepKakkar
Chapter 15: Drug-Drug Interactions for Nucleic Acid-based Derivatives
Jian Wang and Hong Zhao
Appendice: Monographs of Drug-Drug Interactions for Therapeutic Biologics
Author Information
HONGHUI ZHOU, PhD, is Senior Scientific Director and Janssen Fellow, Janssen Research & Development, LLC, Johnson & Johnson, where he heads the Pharmacokinetics & Pharma-codynamics Department within Biologics Clinical Pharmacology. Board-certified by the American Board of Clinical Pharmacology and an American College of Clinical Pharmacology Fellow, Dr. Zhou has authored more than 150 peer-reviewed scientific papers, book chapters, and conference abstracts in pharmacokinetics, pharmacodynamics, and drug-drug interactions.
BERND MEIBOHM, PhD, is Professor of Pharmaceutical Sciences and Associate Dean for Research and Graduate Programs at the College of Pharmacy, The University of Tennessee Health Science Center. Dr. Meibohm is a Fellow of the American Association of Pharmaceutical Scientists and the American College of Clinical Pharmacology.
Fax91 448 21 88
DirC / Raimundo Lulio, 1, 28010 Madrid, España.
Mailpedidosweb@axon.esPrivacidadCondiciones de ventaQuiénes SomosAvisoContacto© 2021 Axón Librería S.L.
v1.47.1